Author:
Barry A. L.,Fuchs P. C.,Thornsberry C.,McLaughlin J. C.,Jenkins S. G.,Hardy D. J.,Allen S. D.
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Microbiology (medical),General Medicine
Reference6 articles.
1. Eliopoulos GM, Klimm K, Eliopoulos CT, Ferraro MJ, Moellering RC: In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of gram-positive bacteria. Antimicrobial Agents and Chemotherapy 1993, 37: 366–370.
2. Gooding BB, Jones RN: In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrobial Agents and Chemotherapy 1993, 37: 349–353 (Erratum, 38:909).
3. Neu HC, Chin N: In vitro activity of the new fluoroquinolone CP-99,219. Antimicrobial Agents and Chemotherapy 1994, 38: 2615–2622.
4. Spangler SK, Jacobs MR, Appelbaum PC: Activity of CP-99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrobial Agents and Chemotherapy 1994, 38: 2471–2476.
5. National Committee for Clinical Laboratory Standards: Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard M11-A3. NCCLS, Villanova, PA, 1993.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献